Skip to main content
Fig. 4 | BMC Pulmonary Medicine

Fig. 4

From: Folate-modified liposomes mediate the co-delivery of cisplatin with miR-219a-5p for the targeted treatment of cisplatin-resistant lung cancer

Fig. 4

Safety and biocompatibility evaluation of the nanomedicine. (a) CCK-8 assay analyzing the effects of free DDP, Lipo@DDP, Lipo@DDP@miR-219a-5p, and Lipo@DDP@miR-219a-5p@FA on the viability of BEAS-2B cells; (b) Hemolysis assay examining the blood compatibility of the nanocarriers, with the first and fifth tubes representing negative and positive controls, respectively. *p < 0.05

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us